Free Case Evaluation (800) 718-4658
(800) 718-4658
CONTACT US

Free Case Evaluation

Lock-Icon We value your privacy

Valsartan Lawsuit – Valsartan Lawyer – Cancer Claims

Valsartan Lawsuit - Valsartan Lawyer - Cancer ClaimsNadrich Accident Injury Lawyers is representing those who have been diagnosed with cancer after taking valsartan. Call us today for a free consultation if you or a loved one:

  • Took valsartan
  • Were diagnosed with cancer after taking valsartan

We are handling the valsartan litigation on a contingency fee basis, meaning we won’t charge you any fee until and unless we recover compensation on your behalf. We won’t charge an upfront fee or out-of-pocket fee – we’ll only charge a percentage of any compensation we recover for you.

Our law firm has been representing those injured by dangerous drugs since 1990, meaning we have the experience to recover the most money possible on your behalf. We have recovered in excess of $750,000,000 for victims of dangerous drugs and our other clients.

Call us today for a free consultation, text us from this page or fill out this page’s free case evaluation form if you or a loved one was diagnosed with cancer after taking valsartan. We can file a valsartan cancer lawsuit on your behalf seeking financial compensation for medical bills, lost wages, loss of earning capacity, pain, suffering, wrongful death and more. Call us today.

Do I Qualify for a Valsartan Lawsuit?

Our law firm is accepting cases involving the following forms of cancer:

  • Intestinal
  • Rectal/colon/colorectal
  • Liver
  • Gastric/stomach
  • Prostate
  • Esophageal
  • Bladder
  • Blood (including leukemia, multiple myeloma and non-Hodgkin lymphoma)
  • Lung (depending upon smoking history)

In addition, you will need to meet the following criteria in order to qualify for a lawsuit:

  • You need to have proof that you took valsartan for at least six months between 2015 and 2019 before your cancer was diagnosed
  • You need to have a relevant cancer diagnosis, post-2017

Valsartan Lawsuits Explained

Valsartan is a drug which is used to treat high blood pressure. The medication has been the subject of numerous lawsuits over concerns of contaminated valsartan.

2018 saw a discovery that certain products containing valsartan had small amounts of two known carcinogens:

  • N-nitrosodimethylamine (NDMA)
  • N-nitrosodiethylamine (NDEA)

Valsartan recalls were the result of this finding.

Soon after the recalls were issues, numerous lawsuits got filed against manufacturers of valsartan medications. These lawsuits alleged that the manufacturers did not warn consumers adequately about the drugs being contaminated. The lawsuits alleged the manufacturers did not warn consumers adequately that the drugs may cause cancer.

Enough lawsuits alleging similar claims were eventually filed for the lawsuits to be consolidated in New Jersey into the valsartan MDL, or multidistrict litigation.

The lawsuits’ plaintiffs alleged that their damages included injuries such as liver damage and cancer, as well as economic losses. The plaintiffs alleged these damages were the result of them taking contaminated valsartan, and claimed the drug makers knew or should have known the drugs were contaminated yet did not take appropriate action.

An important valsartan lawsuit update occurred in December 2022 when the judge overseeing the MDL allowed expert testimony linking contaminated valsartan to cancer. This ruling allowed valsartan trials to go ahead with the findings of scientific studies able to be used as evidence.

Valsartan Lawsuit Status

The valsartan litigation is still ongoing as of December 2024, with 1,283 pending cases in the MDL. The first valsartan trial in the MDL is set to begin on September 8, 2025.

Compensation Available in a Valsartan Medication Lawsuit

If you have a valsartan medical lawsuit filed on your behalf by our lawyers, we can help you recover financial compensation for:

Medical Bills

Since valsartan has been contaminated with a probable human carcinogen, you may be facing medical expenses related to a cancer diagnosis. In addition, you may require future cancer treatment which will generate even more bills. Our law firm can help you recover financial compensation for any past or future medical bills related to your cancer diagnosis.

Lost Wages

If your cancer diagnosis has caused you to be too sick to work or caused you to miss time from work to attend treatments, our valsartan lawsuit attorneys can help you recover any wages you were unable to earn as a result of your cancer diagnosis.

Loss of Earning Capacity

If your cancer diagnosis has caused you to become permanently disabled, we can help you recover financial compensation for the loss or reduction of your earning capacity that this disability represents as part of a valsartan lawsuit payout.

Pain and Suffering

Cancer is a terrible disease which can cause great amounts of physical pain and mental suffering. Our dangerous drug lawyers have over 30 years of experience in accurately calculating the value of our clients’ pain and suffering as well as ensuring our clients are fairly compensated for their pain and suffering.

Wrongful Death

If you have lost a loved one due to cancer caused by valsartan, unfortunately, financial compensation won’t be able to undo the death of your loved one. However, financial compensation can help ensure your family won’t have to endure financial hardship due to losing your loved one. We can help you recover compensation for the pain, suffering and medical bills of your loved one prior to their passing, as well as the loss of your loved one’s companionship, love, income, household services and spousal benefits. We can also help you recover compensation for things like funeral costs, burial costs, and your grieving and suffering.

Can I File a Lawsuit Over Generic Valsartan?

Yes, you can file a valsartan cancer lawsuit over generic blood pressure medications containing valsartan. Numerous companies have seen lawsuits filed against them over contaminated valsartan, including Zhejiang Huahai and Hetero Labs.

Does Valsartan Cause Cancer?

Valsartan itself has not been found to cause cancer. However, valsartan contaminated with NDMA or NDEA may cause cancer.

According to the ATSDR, workers who are exposed to NDMA might see a higher chance of developing prostate, bladder, liver and stomach cancer, and ingestion of high levels of NDMA might lead to colorectal and stomach cancer. Animals who ingested NDMA develop testicular, kidney, lung and liver cancers.

NDEA has been linked with gastrointestinal tract, lung and liver cancer. NDEA has also led to the offspring of pregnant animals exposed to it developing cancer.

A December 2022 study evaluated the connection between occurrence of cancer and exposure to NDMA found in contaminated valsartan. The researchers analyzed those who took valsartan, between the ages of 40 and 80, from January 2013 to December 2017, without a prior history of cancer.

This analysis involved 1.4 million patients. 986,126 of the patients were exposed to contaminated valsartan and 670,388 were only exposed to valsartan which was not contaminated. These findings found that taking the valsartan was associated with a higher risk of melanoma and liver cancer.

Defendants in the Valsartan Litigation

Numerous defendants exist in the litigation over valsartan. Defendants include each company which was part of the supply chain over the time period from the drug being made to the drug being sold to consumers. The defendants include:

  • Manufacturers of valsartan’s active pharmaceutical ingredient: Aurobindo Pharma, Ltd.; Mylan Laboratories, Ltd.; Hetero USA Inc.; Hetero Drugs, Limited; Hetero Labs, Ltd.; Huahai U.S., Inc; Zhejiang Huahai Pharmaceutical Co., Ltd
  • Manufacturers of finished doses of valsartan: Prinston Pharmaceutical Inc.; Aurolife Pharma, LLC; Aurobindo Pharma, Ltd.; Torrent Pharmaceuticals Ltd.; Actavis Pharma, Inc.; Actavis LLC; Teva Pharmaceuticals USA, Inc.; Mylan Pharmaceuticals, Inc.
  • Distributors of finished doses of valsartan: Camber Pharmaceuticals, Inc.; Torrent Pharma, Inc.; Solco Healthcare U.S., LLC; Aurobindo Pharma USA, Inc.
  • Valsartan wholesalers: McKesson Corporation; Cardinal Health Inc.; AmerisourceBergen Corporation
  • Valsartan repackagers: Major Pharmaceuticals, Inc.; AvKARE, Inc.
  • Pharmacies who sold valsartan: Walmart, Inc.; Walgreen Co.; Rite Aid Corporation; OptumRx; The Kroger Co.; Humana Pharmacy, Inc.; pharmacy entities affiliated with Express Scripts, Inc.; CVS Pharmacy Inc.; Albertson’s LLC

Why Was Valsartan Taken off the Market?

Valsartan Lawsuit - Valsartan Lawyer - Cancer Claims2018 saw the United States Food and Drug Administration recall some products containing valsartan because they were contaminated with the carcinogens NDMA and NDEA.

These impurities were not expected. It is thought that the impurities occurred because of changes to the manufacturing process.

Valsartan drugs are widely used for the treatment of heart failure and high blood pressure, so the recall represented a large public health concern.

The response involved the FDA working with drug makers to remove and reduce the carcinogens from the drugs. Patients were provided with guidance and information by the FDA, including:

  • Guidance to keep taking the drugs until a different treatment option or replacement was provided
  • Contacting a doctor or pharmacist immediately if they haven’t done so

Very large impacts were the result of the recall. Global valsartan sales substantially decreased. Concerns also existed that contaminated drugs could have made their way from developed countries into developing countries.

Is Valsartan Safer Than Lisinopril?

Valsartan is typically considered to be safer than lisinopril. The drug is associated with a lower risk of side effects, particularly cough.

A study found that while 8.4 percent of patients who took valsartan withdrew because of adverse events, 10.2 percent of patients who took lisinopril withdrew because of adverse events. The study found that while only 1 percent of valsartan patients experienced dry cough, 7.2 percent of lisinopril patients experienced dry cough.

Valsartan is more tolerable due to its lower risk of side effects. This is important regarding long-term compliance with treatment.

Both drugs are effective at control of blood pressure. Lisinopril is an ACE inhibitor drug, whereas valsartan is an ARB drug.

Has Valsartan 160MG Been Recalled?

Yes, 160mg valsartan tablets, as well as other size tablets of valsartan, have been recalled numerous types due to contamination.

Camber Pharmaceuticals, in August 2018, recalled 320mg, 160mg, 80mg and 40mg tablets of valsartan due to contamination with NDMA.

American Health Packaging, in March 2019, recalled 160mg valsartan tablets due to contamination with NDEA.

Major Pharmaceuticals, in July 2018, recalled valsartan due to possible NDMA contamination.

A-S Medication Solutions LLC, Remedy Repack, AvKARE, Prinston Pharmaceutical, and Teva Pharmaceuticals have also been affected by recalls of valsartan.

When Will the Valsartan Lawsuit Be Settled?

A definitive timeline regarding the valsartan lawsuits settling does not exist yet as of December 2024. Lawsuits in the litigation are complex and ongoing, and there are multiple plaintiffs and defendants.

The lawsuits are claiming that drugs containing valsartan have been contaminated with carcinogens, and that plaintiffs have developed cancer and other injuries after taking the drugs.

Valsartan’s manufacturers have denied all liability, disputing the allegations in the lawsuits. While some cases have settled, a lot of cases are not yet resolved.

How many cases there are outstanding, how willing the parties are to negotiate, how available evidence is, and the outcomes of trials will all influence the valsartan settlement timeline.

While it is quite possible that it could take several years for the litigation to completely resolve, it is also possible that there are valsartan MDL settlement negotiations and a move for a global valsartan lawsuit settlement before the first trial is set to begin in September 2025.

Is There a Class Action Lawsuit Against Valsartan?

Yes, a class action lawsuit has been filed regarding valsartan. However, this class action lawsuit does not cover those who have been diagnosed with cancer after taking valsartan. If you or a loved one have been diagnosed with cancer after taking valsartan, call us today for a free consultation. We can file an individual lawsuit on your behalf seeking compensation for your cancer. It is important to note that an individual lawsuit is different than a class action lawsuit, and that those with cancer diagnoses can recover far more compensation through an individual lawsuit than by joining a valsartan class action lawsuit.

The class action lawsuit is for those who have purchased contaminated valsartan, took the drug and require medical monitoring for cancer. The class action lawsuit includes:

  • A third party payer class
  • A medical monitoring class
  • A consumer economic loss class

Those who took contaminated valsartan probably received a notice of class action via the mail in December 2023.

Call us today for a free consultation if you are unsure of if you should file an individual lawsuit or join a class action lawsuit. We can advise you of the best path forward depending on your circumstances.

Valsartan Lawsuit Updates

The judge overseeing the valsartan MDL entered an order confirming five lawsuits' selection for a second round of initial bellwether trials. A bellwether trial is a trial which serves as a test case for other trials in an MDL. A lot of people harmed by valsartan have joined the MDL known as MDL 2875. This MDL represents those who have been harmed by contaminated valsartan. The five cases may be able to predict how other trials in the MDL may get decided. As a result, the trials are quite important to MDL plaintiffs.

The parties involved in the valsartan litigation now have new deadlines to meet in 2025. A February 14, 2025 deadline has recently been set for fact discovery. In addition, a deadline for identification of expert witnesses has been set for February 28, 2025. These updates may not seem huge. However, they are an indication that the valsartan litigation continues to move forward. This good news for all plaintiffs as well as potential plaintiffs.

Five cases were added to the valsartan MDL in November. There are now 1,283 pending cases in the MDL.

Letters have been submitted to the judge overseeing the valsartan MDL by the defendants and plaintiffs. The parties presented opinions regarding unresolved case issues in the letters. As an examples, the letter discuss if plaintiffs should dismiss cases against defendants who haven't yet been served with any paperwork. In addition, the letter discuss which cases should proceed to bellwether trials, as well as waivers.

The first bellwether trial in the valsartan MDL has been set for September 8, 2025. This is a lot later than plaintiffs hoped for.

The trial will involve an Alabama man who was diagnosed with liver cancer after using valsartan.

The trial is intended to help plaintiffs and defendants gauge how the juries might respond to certain testimony and evidence which will get repeated through the course of the litigation.

Expert discover in the case will be completed by April 28, 2025. A proposed pretrial order will be submitted by August 11, 2025. A final pretrial conference will be held on August 28, 2025.

There will be a case management virtual conference which will take place on December 4 at 3 PM. This conference will address important matters such as jurisdictional issues regarding track one's bellwether trials. It will also address submissions by the parties regarding Lexecon waivers.

An article was published this week by the American Heart Association. The article discusses the possible benefits of valsartan for cancer patients at high risk who are treated using anthracycline chemotherapy. The article, unfortunately, does not discuss the well-known risks of valsartan. This underscores the vital importance of making sure you rely upon complete and accurate information when you make decisions related to healthcare.

A letter has been sent to the judge overseeing the valsartan MDL by the plaintiffs. The letter explains positions regarding timing of questioning and expert reports. Plaintiffs feel defendants should file expert reports prior to plaintiffs questioning their experts. Plaintiffs feel this is far, it aligns with usual practice, and lets them question experts regarding matters discussed in reports by the defendants' experts.

A case scheduling letter has been sent to the judge by the valsartan MDL's defendants. The letter outlines deadlines for milestones which have been agreed upon, such as case-specific discovery, in a lawsuit that will be a bellwether trial. This letter notes that parties disagree upon appropriate deadlines regarding questioning of experts. This will be discussed more by the parties on November 19.

Eight cases were added to the valsartan MDL in October, bringing the total number of cases to 1,278.

Plaintiffs' lawyers have requested an extension regarding the submission of information. Defendants had drafted a letter which plaintiffs needed to respond to. Defendants sent a letter recommending new deadlines regarding bellwether trial start dates and preparations. Plaintiffs requested an extension beyond the deadline for response, set for November 12. The extension request was granted.

In other news, defendants and plaintiffs have sent letters suggesting schedules for preparations for bellwether trials.

The initial bellwether trial in the valsartan MDL was postponed. A third-party payor claim was chosen. This means an insurance company filed it. Third party payors could have valid fraud claims against valsartan manufacturers such as Novartis. However, these cases are quite different from the claims typically filed by patients or their families. By choosing a claim filed by a patient instead, everyone will be provided a better sense of what parties may expect going forward - such as how likely a global settlement is.

Plaintiffs' lawyers have requested that an expert witness be dismissed. The lawyers have said that the testimony of defendants' expert witness Dr. Chodosh shouldn't be allowed. The lawyers said that while the valsartan trial involves economic loss based upon regulatory standards, Dr. Chodosh is an expert regarding general causation, which is not relevant to the trial. As a result, they claim Dr. Chodosh's testimony fails to be relevant. The judge overseeing the MDL will make a final decision regarding this matter.

The initial bellwether trial in the valsartan MDL will start in November. Oral arguments have been scheduled for October 8. These arguments will address issues which are unresolved regarding testimony and discovery to prepare for the trial.

Six cases got added to the valsartan MDL in September, bringing the total to 1,270 regarding pending cases in the MDL.

A lawsuit has been filed by a deceased Missouri woman's son. The lawsuit claims that his mother developed multiple myeloma because she used valsartan. The lawsuit alleges that negligence occurred on behalf of the defendants, who failed to warn about the drug's dangerous side effects. The complaint is demanding wrongful death damages and punitive damages.

A defendant in the valsartan MDL got ordered to pay over $350,000 worth of sanctions for misconduct during discovery. This is a demonstration of the complexity of the litigation and the high stakes involved. If sanctions during discovery are this large, it's an indication that damages at stake are much larger.

The sanctions were over time spent to address issues related to the deposition of Baohua Chen as well as missing document production. The funds are intended to reimburse common benefit time.

Attorneys for the plaintiffs have a concern that the current schedule regarding trial is not adequate because of the case's complexity. They have proposed that the trial should be started earlier, or that additional time be allowed to accommodate defense arguments and witness testimonies.

Seven cases were added to the MDL in August, bringing the total number of cases pending to 1,264.

An order has been issued which addresses numerous motions which have to do with Special Master Order No. 100. Defendants, including Torrent Pharmaceuticals, Teva Pharmaceuticals, Solco Healthcare and Zhejiang Huahai Pharmaceutical, filed motions which sought to modify or reverse the order. Plaintiffs have also filed a motion which requests modifications to the order.

The court, following a review of the motions as well as the findings of the Special Master, decided to deny the motion from Zhejiang Huahai Pharmaceutical. The motion by the plaintiffs was denied in part and granted in part. Motions by Torrent and Teva were granted.

Jury instructions got altered in order to address issues which are related to Baohua Chen's deposition. Chen is Zhejiang Huahai Pharmaceutical's president. He failed to appear for a deposition which was ordered. The instruction revisions let the jury infer that the testimony of Chen may not have been favorable to defendants, particularly regarding defendants' knowledge of valsartan's contamination, which is a vital issue in the litigation.

Friday will see a hearing resolve numerous disputes between plaintiffs and defendants.

Zhejiang Huahai Pharmaceutical is freaking out over a sanctions order, as shown by a motion which is 31 pages long.

They are arguing that discovery violations' appropriateness be determined by the jury. This contradicts prior rulings by the court.

They are also arguing that sanctions will make legal proceedings more complicate, and may make a mini-trial necessary regarding matters the court has already settled, thus possibly prolonging litigation as well as detracting from primary issues at trial. Logic behind this argument is quite confusing.

Three cases were added to the valsartan MDL in July, bringing the total number of pending cases to 1,257.

A lawsuit was filed by a New Jersey man, who claims he developed colon cancer because he took contaminated valsartan. The lawsuit names Auribindo and Zhejiang as defendants, among others.

The plaintiffs have directly held settlement talks with Torrent and Teva, as well as attended a mediation with Special Masters - this mediation was unsuccessful. The plaintiffs are ready to continue talks with Torrent and Teva.

Settlement talks with Zhejiang Huahai Pharmaceutical, the big defendants, have not gone anywhere. It is difficult to imagine a settlement which is reasonable taking place with them without a few trials resulting in big verdicts.

There are now 1,254 lawsuits pending in the valsartan MDL.

Call a Valsartan Attorney at Our Firm Today for a Free Consultation

Valsartan Lawsuit - Valsartan Lawyer - Cancer ClaimsCall us today for a free consultation if you or a loved one has been diagnosed with cancer after taking contaminated valsartan. Our lawyers have been helping those injured by dangerous drugs since 1990, and our experience will allow us to recover the most financial compensation possible on your behalf.

Remember: we won’t charge any fee to handle your valsartan case until and unless we recover compensation for you, so there’s no risk behind calling us. Call us today.

How Can We Help You?

  • This field is for validation purposes and should be left unchanged.

Lock-Icon We value your privacy
© 2025 Nadrich Accident Injury Lawyers All rights reserved.

Impacted By The Recent Wildfires? Learn More About How We Can Help.

Click Here
X